2025_KDIGO_CKD贫血.pdf 01评估 CKD贫血评估 注:严重缺铁性贫血定义为铁蛋白<45μg/L或基于临床判断(铁蛋白<100μg/L)或无法检测铁蛋白情况下无遗传性病因的小细胞性贫血 02铁剂 铁剂 1.铁蛋白≥700μg/L或TSAT≥40%及系统性感染期间可暂停铁剂 2. 优化口服铁治疗1-3月后效果不佳应考虑换用静脉铁 注1...
Algorithms for red cell transfusion use in CKD patients Additional information in the form of supplementary materials can be found online at /clinical_practice_guidelines/anemia.php Kidney International Supplements (2012) 2, v v 2012 KDIGO KDIGO Board Members Garabed Eknoyan, MD Norbert Lameire, ...
(HD 或 PD ):5D 缩写:CKD :慢性肾脏病;GFR :肾小球滤过率;↑,增加;↓, 降低 ® KDIGO Clinical Practice Guidelines for 6 For Translation Chronic Kidney Disease-Mineral and Bone Disorder Publication Draft version ©2009 Kidney Disease: Improving Global Outcomes June 22, 2009 指南建议分级的命名...
Figure 22. The CKD chronic care model 116 Additional information in the form of supplementary materials can be found online at http://.kdigo/clinical_practice_guidelines/ckd.php vi Kidney International Supplements (2013) 3, vi cont ent s http://.kidney-international ...
[CKD] stage 5) with dialysis is not feasible, and trans- plantation can only be offered as a life-saving therapy if it is practical and cost-effective. Therefore, in providing a comprehensive, evidence-based guideline for the care of ...
6, 7, 8 The ultimate goal of treating LN is to preserve kidney function and reduce the morbidity and mortality associated with chronic kidney disease (CKD) and kidney failure, while minimizing medication-associated toxicities. This chapter makes management recommendations for adults who have SLE ...
The COGS checklist for reporting clinical practice guidelines FIGURES S144 Figure 1. Direct-acting antiviral (DAA) regimens with evidence of effectiveness for various chronic kidney disease (CKD) populations S156 Figure 2. Summary of currently available direct-acting antiviral (DAA) treatment targets ...
MRA可降低CKD患者的血压和蛋白尿(2016 Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease a systematic review and meta-analysis.pdf), a与ACE-I和/或ARB单独应用相比,MRA与ACE-I和/或ARB联合应用时收缩压相对于基线的变化。b 与单独使用ACE-I和/或ARB相...
26、reased VDR and CaSR甲状旁腺在CKD进程中的变化治疗甲旁亢的靶点PTH 分泌 钙敏感受体激动剂(Cinacalcet)PTH 合成 Vitamin D, Cinacalcet甲状旁腺增生 甲状旁腺切除术(PTX)矿物质代谢 饮食、补钙、磷结合剂National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, ...
kdigo贫血指南 KDIGO慢性肾脏病贫血临床实践指南 肾性贫血治疗的临床实践指南 Hb 14 EBPGNoCVD 1999 13 KDOQI 12 1997 KDOQI2001 NoCVD KDOQI中国共识2006～20072010 11 CSN-CVD CVDEBPG 10 CanadaCARI CARI2004 UKNICE 1999 2000 UK2003 9 2002 2006